http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2012202250-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 2012-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff38eee88fd976ad2387245e5ca7881 |
publicationDate | 2012-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2012202250-A1 |
titleOfInvention | Modified iRNA agents |
abstract | The invention relates to iRNA agents, which preferably 5 include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand 10 or other entity, e.g., a lipophilic moiety, e.g., cholesterol, is directly or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents. 3306150_1 (GHMatters) P58751 .AU.2 19/04/12 o=P-o.0 *0 tethering attachment point (R-2) backbone attachment points career LIGAND RRMS 0 A=H A: care* R = ('A~ UA L R'cK N(F) 2 |
priorityDate | 2003-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2526.